High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data.
EGFR
Non-small cell lung cancer
high-dose radiotherapy
oligo-progression
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
08
04
2020
revised:
16
04
2020
accepted:
17
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Local ablative treatments for oligo-progressive, EGFR mutated non-small cell lung cancer (mut-NCSLC) may improve long-term disease control and survival. We analyzed the efficacy of hypo-fractionated, high-dose radiation therapy (HDRT), in association with prolonged EGFR tyrosine kinase inhibitors (TKI) in oligo-progressive, EGFR mutant-NSCLC. Progression-free survival-1 (PFS-1, date from initiation of TKI therapy until oligo-progression or death), and progression-free survival-2 (PFS-2, date of focal progression until further progression or death) were evaluated. Thirty-six patients were analyzed. The median PFS 1 was 12.5 months. HDHRT consisted of intensity-modulated RT and stereotactic RT in 23 (64%) and 13 (36%) patients respectively. The median PFS 2 was 6.3 months. Overall survival was 38.7 months. Hypo-fractionated HDRT plus TKI therapy, is associated with a significant prolongation of disease control (overall PFS: 18.8 months), with manageable side effects. These real-world data support the use of local ablative approaches in oligo-progressive EGFR mut-NSCLC.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Local ablative treatments for oligo-progressive, EGFR mutated non-small cell lung cancer (mut-NCSLC) may improve long-term disease control and survival. We analyzed the efficacy of hypo-fractionated, high-dose radiation therapy (HDRT), in association with prolonged EGFR tyrosine kinase inhibitors (TKI) in oligo-progressive, EGFR mutant-NSCLC.
PATIENTS AND METHODS
METHODS
Progression-free survival-1 (PFS-1, date from initiation of TKI therapy until oligo-progression or death), and progression-free survival-2 (PFS-2, date of focal progression until further progression or death) were evaluated.
RESULTS
RESULTS
Thirty-six patients were analyzed. The median PFS 1 was 12.5 months. HDHRT consisted of intensity-modulated RT and stereotactic RT in 23 (64%) and 13 (36%) patients respectively. The median PFS 2 was 6.3 months. Overall survival was 38.7 months.
CONCLUSION
CONCLUSIONS
Hypo-fractionated HDRT plus TKI therapy, is associated with a significant prolongation of disease control (overall PFS: 18.8 months), with manageable side effects. These real-world data support the use of local ablative approaches in oligo-progressive EGFR mut-NSCLC.
Identifiants
pubmed: 32606174
pii: 34/4/2009
doi: 10.21873/invivo.11999
pmc: PMC7439904
doi:
Substances chimiques
Protein Kinase Inhibitors
0
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2009-2014Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):880-7
pubmed: 24867533
Clin Cancer Res. 2011 Oct 1;17(19):6298-303
pubmed: 21856766
J Thorac Oncol. 2012 Dec;7(12):1807-1814
pubmed: 23154552
Expert Rev Clin Pharmacol. 2015;8(4):461-77
pubmed: 26068305
Lung Cancer (Auckl). 2017 Aug 18;8:109-125
pubmed: 28860885
Cancer Discov. 2017 Jul 20;:
pubmed: 28729406
J Oncol Pract. 2018 Jan;14(1):23-31
pubmed: 29324212
Lung Cancer. 2013 Nov;82(2):197-203
pubmed: 24051084
J Thorac Dis. 2017 Feb;9(2):310-317
pubmed: 28275479
J Thorac Oncol. 2015 Nov;10(11):1515-22
pubmed: 26536193
Neurosurg Rev. 2016 Jul;39(3):495-504
pubmed: 27106896
JAMA Oncol. 2016 Mar;2(3):305-12
pubmed: 26720423
Clin Lung Cancer. 2014 Sep;15(5):346-55
pubmed: 24894943
Cancer. 2015 Aug 1;121(15):2570-7
pubmed: 25876525
Br J Radiol. 2017 Apr;90(1072):20170022
pubmed: 28256924
Transl Lung Cancer Res. 2019 Feb;8(1):97-106
pubmed: 30788239
Am J Clin Oncol. 2017 Aug;40(4):418-422
pubmed: 25647831
Nat Rev Clin Oncol. 2011 Jun;8(6):378-82
pubmed: 21423255
Front Oncol. 2017 Sep 19;7:210
pubmed: 28975081
Cancer Treat Rev. 2017 Feb;53:25-37
pubmed: 28056412
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Ann Oncol. 2019 May;30(5):863-870
pubmed: 31987360
J Clin Oncol. 2014 Dec 1;32(34):3824-30
pubmed: 25349291
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Clin Lung Cancer. 2017 Nov;18(6):595-606
pubmed: 28377206
Lancet Oncol. 2016 Dec;17(12):1672-1682
pubmed: 27789196
Lancet Oncol. 2013 Jan;14(1):e28-37
pubmed: 23276369
Nat Rev Clin Oncol. 2014 Aug;11(8):473-81
pubmed: 24981256
J Thorac Oncol. 2013 Mar;8(3):346-51
pubmed: 23407558
Lung Cancer. 2013 Sep;81(3):440-444
pubmed: 23810573